Seascape
Would you like to react to this message? Create an account in a few clicks or log in to continue.
Seascape

Life in Miramar Beach and the surrounding planets
 
HomeLatest imagesSearchRegisterLog in

 

 Emphysema: Stopping Progression and Reversing Damage

Go down 
AuthorMessage
justdhf
Admin
justdhf


Posts : 1872
Join date : 2008-10-30
Age : 72
Location : Florida

Emphysema: Stopping Progression and Reversing Damage Empty
PostSubject: Emphysema: Stopping Progression and Reversing Damage   Emphysema: Stopping Progression and Reversing Damage Icon_minitimeTue Feb 05, 2013 6:26 pm

Emphysema: Stopping Progression and Reversing Damage

http://www.disabled-world.com/health/respiratory/emphysema.php

Emphysema: Stopping Progression and Reversing Damage

Author: Boston University Medical Center
Subject Category: Respiratory Disorders
Published: Sep 01, 2012 (Revised: Sep 01, 2012)

Abstract: Research finds compound used in some skin creams may halt the progression of emphysema and reverse damage caused by the disease.

Document Detail: BUSM researchers find potential key to halt progression, reverse damage from emphysema - A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

The study, which is published in BioMed Central's open access journal Genome Medicine, also demonstrates the potential impact of using genomic technologies to identify new possible treatments for diseases using existing drugs and compounds.

Chronic obstructive pulmonary disease (COPD) is a chronic, progressive lung disease that comprises emphysema, small airway obstruction and/or chronic bronchitis leading to the loss of lung function.

Tobacco smoke and other irritants cause oxidative stress and chronic inflammation, which over time destroys lung alveolar cells and results in emphysema. Without these cells, the lungs are not able to efficiently exchange oxygen for carbon dioxide, causing shortness of breath and low blood oxygen levels.

According to the National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI), COPD is the third leading cause of death in the United States and results in approximately 120,000 deaths each year. While there are treatments and lifestyle changes that can help people cope with COPD, there currently is no cure and there are no effective therapies to reduce the rate of lung function decline that occurs as the disease progresses.

"Given the high costs, both direct and indirect, associated with COPD, there is an urgent need to identify novel approaches to treat the disease," said Avrum Spira, MD, MSc, Alexander Graham Bell professor of medicine and chief of the division of computational biomedicine at BUSM, who was one of the study's senior leaders. Spira also is a physician in the pulmonary, critical care and allergy department at Boston Medical Center.

Researchers took cells from lungs donated by patients undergoing a double lung transplant because their lungs were irrevocably damaged by COPD and found 127 genes had changes in activity as disease severity increased within the lung. The genes that showed increased activity included several that are associated with inflammation, such as those involved in signalling to B-cells (the immune system cells that make antibodies).

In contrast, the genes involved in maintaining cellular structure and normal cellular function, along with the growth factors TGFβ and VEGF, were down-regulated and showed decreased activity. Genes that control the ability of the cells to stick together (cell adhesion), produce the protein matrix that normally surrounds the cells and promote the normal association between lung cells and blood vessels were among the genes in this category.

Using genomic technologies and computational methods, the researchers identified genetic activity defects that occur as emphysema progresses and matched these defects with compounds that could reverse the damage. "Our study results showed that the way genes were affected by the compound GHK, a drug identified in the 1970s, was the complete opposite of the pattern we had seen in the cells damaged by emphysema," said Marc Lenburg, PhD, associate professor in computational biomedicine and bioinformatics at BUSM and one of the study's senior authors.

"What got us especially excited was that previous studies had shown that GHK could accelerate wound repair when applied to the skin," said Joshua Campbell, PhD, a post-doctoral fellow working with Spira and Lenburg who served as the study's first author. "This made us think that GHK could have potential as a therapy for COPD."

"When we tested GHK on cells from the damaged lungs of smokers with COPD, we saw an improvement in the structure of their actin cytoskeleton and in cell adhesion, especially to collagen," said James Hogg, MD, from the University of British Columbia and one of the study's senior authors. "GHK also restored the ability of cells to reorganize themselves to repair wounds and construct the contractile filaments essential for alveolar tissue repair."

GHK is a natural peptide found in human plasma, but the amount present decreases with age.

While more testing needs to be done on its effects in COPD, these early results are very promising. Therapeutic studies with GHK in animal models of COPD are now underway with the ultimate goal of moving this compound into clinical trials. As more gene activity signatures are discovered, this method of matching drug to disease may provide a rapid method for discovering potential uses for existing drugs and compounds.

"Beyond the identification of a potential new COPD drug, the research team developed a cost-effective approach to study COPD at the molecular level across the entire lung, and then screen potential drug candidates," said James Kiley, PhD, director of the NHLBI's Division of Lung Diseases, who supported this work. "This work demonstrates the potential of using genomics data to drive clinical research."

Research reported in this published article was supported by the NHLBI under award number R01 HL095388 and through the National Institutes of Health under award number UL1 TR000157 (Boston University Clinical and Translational Science Institute). Researchers from the University of British Columbia, the University Medical Center Groningen and the University of Pennsylvania also collaborated on this study.





Last edited by justdhf on Tue Jan 28, 2014 3:30 pm; edited 1 time in total
Back to top Go down
http://domania.us/justdhf/index.html
justdhf
Admin
justdhf


Posts : 1872
Join date : 2008-10-30
Age : 72
Location : Florida

Emphysema: Stopping Progression and Reversing Damage Empty
PostSubject: Some Bad News   Emphysema: Stopping Progression and Reversing Damage Icon_minitimeTue Apr 23, 2013 10:33 pm

My primary Doctor has looked into the Gly-His-Lys (GHK) and gave me a number to call and talk to the man who is researching it. His name is Loren Pickart. He was a very nice person and was pleasant to talk to. He told me he is not a medical doctor but he is a biochemist and scientist that more or less works for cosmetic companies and studies medicine and discovers medicines used in cosmetics and creams.
He said him and a few other scientist had discovered that GHK had some medicinal properties that showed some promising results. He has been studying this for about 10 years. Over seas is more progressive with this than the USA.

He told me the FDA is fighting him as hard as they can to suppress his findings. He said they are trying to put him our of business if he don't shut up. But he said he is not going to give up because there are a number of things GHK can do. He told me he is writing a book that he hopes to have out soon if the government doesn't stop it from being published.

I told him I got the article out of the Boston University Medical Center and he said "Yes, there have been a few Medical papers willing to publish his work. His work is also published in BioMed Central open access journal Genome Medicine.

Pickart told me he is really disappointed in the FDA and wish he could help me but he is not giving up the fight.

My primary doctor says he will call Pickart and see what he find out and will also try and find out more about GHK. So far he has found out it would have to be administered intravenously. There is still a lot to find out but we are not going to give up yet.

GHK (GHK-Cu) Has been shown in multiple scientific studies to possess significant biological benefits to the human body. Some of these benefits which have already been proven through many research studies world wide are the following:
* INCREASED WOUND HEALING
* INCREASES IMMUNE DEFENSE
* ANTI-OXIDANT & ANTI - INFLAMMATORY EFFECTS
* STIMULATION OF NEW COLLAGEN IN AGING SKIN
* ANTI-AGING BENEFITS FOR PHOTO-AGED & WRINKLED SKIN
* STRONGLY STIMULATES HAIR GROWTH.
* PROMOTES NERVE REGENERATION.
* ALLOWS EPIDERMAL STEM CELLS TO REPAIR DAMAGED SKIN.
* SHOWN TO REVERSE THE METASTATIC SPREAD OF COLON CANCER.

http://skinbiology.com/copper-peptides-chemistry-references.html

http://store.reverseskinaging.com/ProductDetails.asp?ProductCode=87
_________________
Back to top Go down
http://domania.us/justdhf/index.html
 
Emphysema: Stopping Progression and Reversing Damage
Back to top 
Page 1 of 1
 Similar topics
-
» Halt progression, reverse damage from emphysema
» Temple University Hospital Investigating Whether Ibuprofen Can Reverse the Effects of Emphysema
» History of Emphysema
» Emphysema is a progressive lung disease
» Irish team behind emphysema breakthrough

Permissions in this forum:You cannot reply to topics in this forum
Seascape :: General :: General :: Health-
Jump to: